Guide Management of Nonalcoholic Fatty Liver Disease

July 2022

You’ll see more focus on managing nonalcoholic fatty liver disease (NAFLD)...partly due to new guidelines.

It’s being called a “sleeper epidemic.” About 1 in 4 patients have this steatosis...but most don’t have symptoms.

NAFLD often goes hand in hand with CV risk factors, such as insulin resistance or diabetes...obesity...and dyslipidemia.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Antidepressants Individualize the Choice of Antidepressant Combos
COVID-19 Help Reduce Barriers to Paxlovid for COVID-19
New Drugs Consider the Role of Mounjaro for Type 2 Diabetes
Dermatitis Answer Questions About Dandruff or Cradle Cap
Liver Disease Guide Management of Nonalcoholic Fatty Liver Disease
Magnesium Answer FAQs About Magnesium Supplements
Biologics Be Familiar With the Laundry List of Uses for Dupixent
Education and Training Be a Standout Preceptor
Supplements Calm the Buzz About Collagen Supplements
Diabetes Consider Subcutaneous Insulin to Manage DKA
Stroke Update Your Intracerebral Hemorrhage Protocols
Psychiatry Explain the Role of SL Dexmedetomidine in Acute Agitation